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Rationale, aims, and objectives: The Ghent Older People's Prescriptions commu-
nity Pharmacy Screening (GheOP3S)‐tool was recently developed as an explicit
screening tool to detect drug‐related problems (DRPs) and to help in performing med-
ication reviews. In this study, we aimed (a) to describe the characteristics of the
detected DRPs and the subsequent pharmacists' recommendations with their accep-
tance and implementation rate resulting from a pharmacist‐led medication review
using the GheOP3S‐tool and (b) to assess the potential impact of the intervention.
Method: Prospective observational study in community‐dwelling older patients (70
years or older, using five or more medications). Community pharmacists performed
medication reviews resulting in the documentation of “GheOP3S‐related DRPs” and
“other DRPs” with corresponding pharmacists' recommendations. Acceptance was
recorded during face‐to‐face pharmacist‐general practitioner (GP) meetings. Imple-
mentation was assessed after a 3‐month follow‐up by consulting the electronic
pharmacy record, the patient, and/or GP. The potential impact on the number of med-
ications, the number of “GheOP3S‐related DRPs”, the anticholinergic and sedative
burden quantified by the Drug Burden Index (DBI), and medication costs was
assessed by a pre‐post comparison of the patients' medication lists.
Results: Twenty‐one pharmacists detected 470 DRPs with a median (IQR) of 6
(4‐8) per patient in 75 patients (about half “GheOP3S‐related DRPs” and half “other
DRPs”). Most prevalent recommendations were stopping (22.9%) and substituting
(18.9%) medication. Overall acceptance was 66.9%. At follow‐up, 42.9% of all recom-
mendations were implemented. The number of GheOP3S‐criteria (P < .001) and the
DBI scores (P = .033) significantly differed from baseline. This was not the case for
the number of chronic medications and medication costs.© 2019 John Wiley & Sons, Ltd.wileyonlinelibrary.com/journal/jep 1
2 FOUBERT ET AL.Conclusions: This study demonstrates a relatively high acceptance of pharmacists'
recommendations, although implementation could be improved. Pharmacist‐led med-
ication reviews with multidisciplinary meetings using the GheOP3S‐tool can have a
potential impact on the number of DRPs and the anticholinergic and sedative burden
of patients.
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polypharmacy1 | INTRODUCTION
Polypharmacy—often described as the concurrent use of at least five
chronic medications1,2—is common in older people and is often nec-
essary to manage multimorbidity. However, it can also become a
problem. Polypharmacy inappropriateness may arise if the risk of
harm from medications is likely to outweigh the benefits, eg, when
pill burden hampers adherence or when medications interact with
each other,3 leading to an increased risk of drug‐related problems
(DRPs).4 A DRP can be defined as an event or circumstance involving
medication therapy that actually or potentially interferes with
desired health outcomes.5 DRPs are associated with higher health
care utilization (eg, hospitalisations and emergency department
visits), reduced quality of life, and increased health care costs.6-9
Therefore, health care providers are urged to take action in the pre-
vention of iatrogenic harm related to medications. In this context,
the World Health Organization calls for a worldwide commitment
to reduce severe and avoidable medication‐related harm10 with
50% by 2022.
Medication review, consisting of a structured evaluation of a
patient's pharmacotherapy, has been proposed as a strategy to
identify and resolve DRPs.11 Several studies have shown a positive
impact of medication review on the quality of medication use (eg,
the number of [appropriate] medications12,13 and DRPs13) and on
disease‐specific outcomes (eg, glycosylated haemoglobin, blood
pressure, and cholesterol).12 However, a forthright effect on major
outcomes such as hospitalisation,12-14 mortality,12,13 health‐related
quality of life,14,15 and health care costs13,15 has not yet been
demonstrated.
There is an international trend to involve community pharmacists
in performing medication reviews, because of their specific
medication‐related knowledge. However, performing medication
reviews is not a common practice in Belgian community pharmacies
nor is it reimbursed by the health insurances. To facilitate the
detection of DRPs in a structured way and thereby the implementa-
tion of medication review in the Belgian community pharmacy prac-
tice, we have recently developed the Ghent Older People's
Prescriptions community Pharmacy Screening (GheOP3S)‐tool.16 This
is an explicit screening tool for detecting DRPs with high clinical rel-
evance in community‐dwelling older people, without the need forclinical patient data. It was specifically designed for use in the com-
munity pharmacy setting. The GheOP3S‐tool encompasses overuse
and misuse (of potentially inappropriate medications), underuse
(potential prescribing omissions), drug‐drug interactions (DDIs), and
pharmaceutical care–related criteria (eg, monitoring medication
adherence).
So far, we have found that GheOP3S‐criteria are highly
prevalent among older adults with polypharmacy in primary care.17-
19 However, the acceptance and implementation of pharmacists' rec-
ommendations resulting from a multidisciplinary medication review
process using the GheOP3S‐tool have not yet been studied in this
population. Therefore, the current study was designed to embed the
use of the GheOP3S‐tool in a medication review process in
community‐dwelling older patients with polypharmacy. The main
objectives were (a) to investigate the characteristics of the detected
DRPs and the subsequent pharmacists' recommendations with their
acceptance and implementation by general practitioners (GPs) and
(b) to explore the potential impact of this medication review process
on the number of medications, the number of “GheOP3S‐related
DRPs,” the anticholinergic and sedative burden, and medication costs.2 | METHODS
2.1 | Study design, setting, and participants
This study resulted from a collaboration between the Association of
Belgian Pharmacies, KU Leuven, Université Libre de Bruxelles, and
Ghent University, which was set up to investigate the implementation
of pharmacist‐led medication reviews in primary care in Belgium.20
We conducted a prospective observational study from December
2016 to October 2017 in a convenience sample of 12 community
pharmacies in Belgium. These pharmacies employed at least one phar-
macist who had previously received training in performing medication
review using the GheOP3S‐tool and who was willing to engage in a
face‐to‐face discussion with the GP about the results of the medica-
tion review. More than one pharmacist per pharmacy could
participate.
Since this was the first time that pharmacists would perform
multidisciplinary medication reviews using the GheOP3S‐tool, the
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GPs who were willing to participate in the study and with whom they
had patients in common. The pharmacist and GP selected together
community‐dwelling patients aged 70 years or older and using five
or more chronic medications (defined as medications without a stop
date) who could (in their opinion) benefit from a medication review
(eg, patients with a recent hospitalisation, a recent fall, suspected
adverse drug reactions (ADRs), and suspected problems with
adherence). Patients not able to take part in an interview with the
pharmacist (eg, insufficient knowledge of Dutch language, insufficient
cognitive skills) were not eligible for inclusion. Selected patients
were subsequently invited to participate in the study by the pharma-
cist. It was planned to recruit at least seven patients per pharmacy
practice.
The ethical committee of Ghent University Hospital granted
ethical approval. All patients provided written informed consent.
This study was reported in accordance with the “Strengthening
The Reporting of Observational Studies in Epidemiology” (STROBE)
guidelines.21
2.2 | Intervention
Before the start of the study, participating pharmacists received pro-
tocol training. Pharmacists conducted an intermediate medication
review type 2a (which is based on medication history and patient
information, according to Pharmaceutical Care Network Europe typol-
ogy of medication reviews22) using the GheOP3S‐tool. They were free
to use other sources of information (eg, other medication screening
tools, medication interaction checkers, national guidelines) in addition
to the GheOP3S‐tool.
The medication review process consisted of six steps:
1. A preparation step including an extraction of the current medica-
tion use and previously reported DRPs (eg, allergies, contraindica-
tions, and nonadherence) from the electronic pharmacy record.
2. A pharmacotherapeutic anamnesis: A face‐to‐face patient inter-
view at the pharmacy or at the patient's home to:• Collect basic patient characteristics (age, gender, weight,
length, functional status, and self‐rated health).23
• Collect smoking status, alcohol use, diet, and cognitive func-
tion using the Mini‐Cog test.24
• Check the accuracy of the current medication list and poten-
tial medication indications.
• Identify experienced ADRs and (practical) problems with
medication intake.
• Assess medication adherence and the patient perceived med-
ication effectiveness.
• Discuss the patient's experiences, expectations, and prefer-
ences about their medication.3. A pharmacotherapeutic analysis consisting of the following:– Medication screening with the GheOP3S‐tool to detect
“GheOP3S‐related DRPs”. Pharmacists were advised toexclude the GheOP3S‐criteria concerning direct oral anticoag-
ulants (in light of the emerging evidence25) and to elevate the
threshold for the 10‐year probability of major osteoporotic
fractures from 10% to 20%26 for the GheOP3S‐criterion
“patient has an elevated risk for osteoporosis and is not pre-
scribed calcium/vitamin D supplementation”.
– Identification of “other DRPs” using other sources of informa-
tion (including DRPs detected during the patient interview).
Additional information (eg, confirmation of diagnosis) could
be acquired by contacting the GP or in the next step, the
face‐to‐face discussion with the GP.
– Development of a pharmaceutical care plan with
the pharmacist's recommendations to improve medication
appropriateness.4. A face‐to‐face pharmacist‐GP meeting to discuss the relevance
(for the individual patient) of the pharmacist's recommendations,
to seek agreement on the interventions in the pharmaceutical
care plan, and to prioritize all identified DRPs with their interven-
tions in an agreed action plan. Priorities were discussed between
the pharmacist and GP, taking into account the information phar-
macists received during the patient interview (eg, the patient's
preferences or expectations) and the instructions given in the
study protocol (eg, What is currently a problem for the patient?;
Is the patient's safety compromised?; Which conditions could be
treated more effectively?; What is the life expectancy of the
patient?).
5. A discussion between the patient and pharmacist and/or GP to
seek agreement on proposed interventions, resulting in a final
action plan. In addition, the patient received an updated medica-
tion list (including agreed medication changes) from the
pharmacist.
6. A follow‐up moment (3 months after step 5) to evaluate
the implementation of pharmacist's recommendations. Pharmacists
assessed the implementation rate by consulting the electronic
pharmacy record (eg, to check whether medications were actually
stopped or started), the patient (eg, to check whether information
was transmitted), and/or the GP (eg, to check whether therapy
monitoring was carried out).
During the study, pharmacists were supported by the researcher
who monthly called them to discuss possible problems or questions
and to assess the progress of the study. A financial incentive of 60€
per included patient was provided to the participating pharmacists at
the end of the study.2.3 | Data collection
Pharmacists recorded all patient data and interventions in a case
report form (CRF) developed by the research team (available upon
request). They also recorded for each patient how much time they
spent to each step of the intervention.
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All medications were coded using the Anatomical Therapeutic Chemi-
cal Classification System (ATC) formulated by the Word Health Orga-
nisation Collaborating Centre for Drug Statistics Methodology.27 All
DRPs and pharmacists' recommendations were classified by the
researcher and peer reviewed through discussion with a second phar-
macist using the Pharmacists' Documentation of Interventions in
Seamless Care (PharmDISC) classification system.28
Primary outcomes were the number and type of DRPs, the subse-
quent pharmacists' recommendations, and the GPs' acceptance and
implementation rate of pharmacists' recommendations. DRPs were
categorized as either “GheOP3S‐related DRPs” when it was clear from
the CRF that the detection of the DRP resulted from screening with
the GheOP3S‐tool or as “other DRPs” when the detected DRP was
not recorded in the CRF as a GheOP3S‐criterion. Acceptance and
implementation were categorized as “full,” “partial,” “not,” and “not
recorded.” Acceptance was classified as “partial” when (a) the GP
accepted dose tapering but no full stop, (b) when the GP accepted
to switch medication but preferred another medication than the one
proposed by the pharmacist, or (c) if only one recommendation was
accepted in case of a combined recommendation (eg, pharmacist
advised to taper two benzodiazepines and GP wanted to taper only
one). Implementation was classified as “partial” when (a) the GP
accepted to stop medication using tapering, but the medication
appeared to be not fully stopped at 3‐month follow‐up or (b) if only
one recommendation was implemented in case of a combined recom-
mendation. Acceptance and implementation rate were determined by
the ratio of the number of relevant pharmacists' recommendations
that were fully or partially accepted/implemented by the GP to the
total number of relevant pharmacists' recommendations.
In addition, the potential impact of the intervention was assessed
by comparing patient's medication list between baseline (after the
patient interview) and 3‐month follow‐up in terms of the following:1. The number of medications.
2. The number of “GheOP3S‐related DRPs”.
3. The Drug Burden Index (DBI) score of all oral chronic medications,
which was used as a proxy for medication safety. The DBI is based
on a linear additive model and quantifies the cumulative
anticholinergic and sedative medication burden in older adults.29
A higher anticholinergic and sedative burden can increase the risk
of impaired cognitive and physical function and the frequency of
falls.30,31 Scores were calculated using the formula DBI = ∑ D/(D
+ δ), where D is the daily dose of every anticholinergic or sedative
medication used by the patient and δ is the minimum recom-
mended daily dose as listed by the Belgian Commented Medica-
tions Repertory.32 Medication was considered anticholinergic
when present in the GheOP3S‐tool (“medications with high risk
for anticholinergic side‐effects,” based on the list of Duran
et al33) or sedative based on ATC‐code (N01A, N02A, N05,
N06A, N07CA, and R06).4. Medication costs per day (in euro): These costs were calculated for
both the patient (out‐of‐pocket medication cost) and the Belgian
health care insurance system (National Institute for Health and
Disability Insurance, NIHDI) (third party reimbursement). Topical
agents and as needed medications were excluded.
Statistical analysis was performed using SPSS Statistics version
25. A Wilcoxon signed rank test was used to compare the medians
of two discrete variables (number of chronic medications and
number of GheOP3S‐criteria). A Mann‐Whitney U Test was used to
compare the acceptance and implementation rate of recommenda-
tions related to “GheOP3S‐related DRPs” and “other DRPs.” A paired
t test was used to compare the means of two (paired) continuous
variables (DBI scores and medication costs). Comparisons were made
between data at baseline (after the patient interview) and 3‐month
follow‐up. A two‐tailed P value of less than .05 was considered
significant.3 | RESULTS
3.1 | Sample characteristics
In the 12 participating community pharmacies, 21 pharmacists
collaborated with 44 GPs. Eighty‐nine patients were invited for study
participation, of which 10 (11.2%) refused to participate, resulting in
79 included patients (Figure 1A). Four patients were excluded from
analysis, resulting in a final sample of 75 patients (Figure 1A). Pharma-
cist and patient characteristics are detailed in Table 1.3.2 | Intervention characteristics
3.2.1 | Baseline DRPs and resulting pharmacists'
recommendations
Pharmacists detected a total of 470 DRPs in 75 patients with a
median (IQR) of 6 (4‐8) per patient. The most prevalent types of
DRPs (according to the PharmDISC classification system) were
“contraindication” (19.1%), “interaction” (15.3%), and “missing patient
documentation or information” (10.0%) (Table 2). Forty‐nine percent
of DRPs were “GheOP3S‐related DRPs” (n = 230). Screening with
the GheOP3S‐tool mainly attributed to the detection of DRPs
related to overuse/misuse (PharmDISC categories C1.2 contraindica-
tion, C1.3 interaction, C4.3 inappropriate therapy duration, and C3.2
overdose, see Table 2) and underuse (PharmDISC category C1.1 no
concordance with guidelines, only suboptimal therapy possible,
Table 2). Fifteen GheOP3S‐criteria accounted for more than three
quarters (76.5%) of all detected GheOP3S‐criteria. Most prevalent
GheOP3S‐criteria (n, % of patients) were “any intermediate acting
benzodiazepine or Z‐drug at full dose or any dose 30 subsequent
days or more” (34, 45.3%), “any antidepressant 1 year or more”
(21, 28.0%), “the patient has an elevated risk for osteoporosis and
is not prescribed calcium/vitamin D supplementation” (21, 28.0%),
FIGURE 1 Study flowchart with A, recruitment of participants and B, intervention characteristics. DRP, drug‐related problem; GP: general
practitioner; GheOP3S: Ghent Older People's Prescriptions community Pharmacy Screening; *Eligible patients: Patients on which both the
pharmacist and GP agreed a medication review could be beneficial
FOUBERT ET AL. 5“any proton pump inhibitor (PPI) at full dose 8 weeks or more”
(12, 16.0%), “oral antidiabetics/insulin + cardioselective β‐blocker”
(10, 13.3%), and “any combination of anticholinergic medications”
(10, 13.3%). “Other DRPs” constituted 51.1% (n = 240) of all
detected DRPs. About one‐fourth (25.7%, 121/470) of all DRPs
were exclusively identified on the basis of patient interviews (eg,
untreated symptoms, ADRs, nonadherence, and administration
technique errors).
The most common pharmacists' recommendations were to stop
medication (22.9%), to substitute medication (18.9%), to monitor
therapy (14.5%), and to adjust dose (12.8%) (Table 2). Pharmacists
did not record their recommendation for 24 DRPs (5.1%, 24/470)
(Figure 1B1).3.2.2 | Acceptance of pharmacists'
recommendations
During the pharmacist‐GP meetings, 20 of 446 (4.5%) pharmacists'
recommendations were judged as not relevant for the specific
patient (Figure 1B2). These were all recommendations for
laboratory parameter monitoring that had already been provided by
the GP (n = 17) or recommendations related to medication that
had already been stopped or started in the period between the
pharmacotherapeutic analysis by the pharmacist and the
pharmacist‐GP meeting (n = 3). For 33 (7.7%, 33/426) recommenda-
tions, the pharmacist did not record the acceptance. The GPs (fully
or partially) accepted 66.9% (285/426) of the recommendations
TABLE 1 Baseline characteristics of the participants
Pharmacists (n = 21)
Age (y) 41.5 ± 10.3
Female gender 16 (76.2)
Work experience in the community pharmacy (y) 17.8 ± 10.3
Patients (n = 75)
Age (y) 78.3 ± 5.4
Age ≥ 85 y 10 (13.3)
Gender, female 46 (61.3)
Number of chronic medications 11 [8‐13]
Most frequently used chronic medicationsa
Antithrombotic agents (B01A) 54 (72.0)
Lipid modifying agents, plain (C10A) 52 (69.3)
β‐blocking agents (C07A) 46 (61.3)
Drugs for peptic ulcer and gastro‐oesophageal
reflux disease (A02B)
37 (49.3)
Hypnotics and sedatives (N05C) 32 (42.7)
Blood glucose lowering drugs, excl. insulins
(A10B)
27 (36.0)
Antidepressants (N06A) 23 (30.7)
Selective calcium channel blockers with
mainly vascular effects (C08C)
22 (29.3)
Vitamin A and D, incl. combinations
(A11C)
17 (22.7)
High‐ceiling diuretics (C03C) 15 (20.0)
Body Mass Index (kg/m2) (n = 69) 27.3 ± 4.2
Living alone 25 (33.3)
Self‐rated health statusb
Excellent 2 (2.7)





Patient needs help with (bathing/showering,
dressing, toileting, community mobility,
eating, cleaning):
1 daily activity 19 (25.3)
2 daily activities 17 (22.7)
3 daily activities 6 (8.0)
>3 daily activities 4 (5.3)
No help needed 29 (38.7)
Positive for cognitive impairment according to the
Mini‐Cog testc (n = 73)
20 (27.4)
Patients with ≥1 unplanned hospitalisation in past
3 mo
11 (14.7)




Patients with ≥1 fall in past 3 mo 11 (14.7)
Note. Data are presented as: n (%), mean ± SD or median [IQR].
aClassified according to the Anatomical and Therapeutic Classification
(ATC) using the second level (therapeutic main group) (n, % of patients).
bSelf‐rated health was determined by the question “How in general would
you rate your health?” with response options of “excellent, very good,
good, fair, or poor.”
cThe Mini‐Cog test consists of three questions: (a) to recall three unrelated
words, (b) to draw a clock as a recall distractor, and (c) to recall the three
previously unrelated words. Recalling zero words or recalling two or less
words and drawing an abnormal clock were suggestive for cognitive
impairment.24
6 FOUBERT ET AL.(Figure 1B3). Recommendations with high acceptance rate (more
than 70%) were “optimization of administration/route” (82.4%,
14/17), “therapy started” (80.0%, 32/40), and “therapy monitoring”
(78.9%, 45/57) (Table 3).
The main reasons for not accepting pharmacists' recommendations
were the GP perceived medication as still necessary or beneficial
(29.6%, 32/108) and the GP perceived the recommendation to be of
inferior priority (but still relevant) at the moment (25.9%, 28/108)
(Appendix S1). Acceptance rates of recommendations related to
“GheOP3S‐related DRPs” (67.2%, 135/201) and recommendations
related to “other DRPs” (66.7%, 150/225) did not statistically differ
(Mann‐Whitney U Test, z = −0.455, P = .684).3.2.3 | Implementation of pharmacists'
recommendations
Overall, 42.9% (183/426, Figure 1B4) of pharmacists' recommenda-
tions were (fully or partially) implemented at 3‐month follow‐up. This
corresponds to 56.1 % of accepted pharmacists' recommendations.
For 22 recommendations, the implementation was not recorded
(5.2%, 22/426). “Application instruction” (100%, 8/8), “clarification/
addition of information” (100%, 6/6), and “in‐depth counselling of
patient” (100%, 6/6) were the recommendations with the highest
implementation rates (Table 3). Main reasons for not implementing
accepted recommendations were the patient refuses recommended
medication change (32.4%, 33/102) and postponement of the inter-
vention (30.4%, 31/102) (Appendix S1). Implementation rates of
recommendations related to “GheOP3S‐related DRPs” (33.3%,
67/201) and “other DRPs” (51.6%, 116/225) did not statistically
differ (Mann‐Whitney U Test, z = −1.289, P = .218).3.2.4 | Time investment
The median (IQR) time investment per medication review was 180
(150‐244) minutes. The anamnesis or patient interview was the most
time‐consuming step. The median (IQR) time investment per step in
the medication review process was preparation step 30 (30‐45)
minutes, anamnesis 60 (50‐90) minutes, medication review (screening
TABLE 2 Baseline DRPs and subsequent pharmacists' recommendations (classified according to the PharmDISC classification system28)
All DRPs [n (%i)] “GheOP3S‐related DRPs” [n (%j)]
n = 470 n = 230
Baseline DRPs
C1.2 Contraindicationa 90 (19.1) 84 (93.3)
C1.3 Interaction (between medications or food) 72 (15.3) 41 (56.9)
C1.7 Missing patient documentation or informationb 47 (10.0) 0 (0.0)
C4.3 Inappropriate therapy duration 46 (9.8) 43 (93.5)
C1.1 No concordance with guidelines, only suboptimal therapy possiblec 42 (8.9) 31 (73.8)
C3.2 Overdose 31 (6.6) 27 (87.1)
C1.4 Drug not indicated 29 (6.2) 0 (0.0)
C1.6 Adverse effect 24 (5.1) 0 (0.0)
C5.4 Financial burden (patient/public health) 15 (3.2) 0 (0.0)
C4.2 Inappropriate application (incorrect use of inhaler or eye drops) 11 (2.3) 0 (0.0)
C1.5 Duplication 10 (2.1) 3 (30.0)
C3.3 Inappropriate monitoring 10 (2.1) 0 (0.0)
C3.1 Underdose 9 (1.9) 1 (11.1)
C4.1 Inappropriate timing or frequency of administration 8 (1.7) 0 (0.0)
C5.1 Insufficient adherence 8 (1.7) 0 (0.0)
C5.2 Insufficient knowledge 8 (1.7) 0 (0.0)
C2.1 Inappropriate dosage form/administration route 6 (1.3) 0 (0.0)
C5.3 Concerns about the treatment (eg, about the number of medications) 2 (0.5) 0 (0.0)
C7.4 Formal/regulatory reason (GP forgot to request reimbursement) 2 (0.4) 0 (0.0)
Recommendation type
D5 Therapy stopped (with or without tapering) 108 (22.9) 75 (69.4)
D1 Substitution (to safer or cheaper medication) 89 (18.9) 49 (55.1)
D12 Therapy monitoringd 68 (14.5) 21 (30.9)
D2 Dose adjustment (to reduce or increase dose) 60 (12.8) 35 (58.3)
D6 Therapy started 42 (8.9) 23 (54.8)
D11 Transmission of informatione 41 (8.7) 7 (17.1)
No recommendation recorded 24 (5.1) 16 (66.7)
D4 Optimization of administration/routef 18 (3.8) 4 (22.2)
D8 Application instruction (training)g 8 (1.7) 0 (0.0)
D10 Clarification/addition of information to the patient's pharmacy recordh 6 (1.3) 0 (0.0)
D7 In‐depth counselling of patient (eg, on adherence) 6 (1.3) 0 (0.0)
Abbreviations: ADR, adverse drug reaction; DDI, drug‐drug interaction; DRP, drug‐related problem; GheOP3S, Ghent Older People's Prescriptions commu-
nity Pharmacy Screening; GP, general practitioner; OTC, over‐the‐counter; PharmDISC, Pharmacists' Documentation of Interventions in Seamless Care.
aFor example, medications contraindicated in patients with decreased kidney function, Parkinson's disease, cognitive impairment, constipation.
bLack of patient information in case notes/laboratory notes: When untreated symptoms (not perceived as an ADR) were not yet communicated to the GP,
eg, dermatological problems, emotional stress, decreased physical activity; or when contraindications or OTC‐medications were missing in the electronic
pharmacy record.
cFor example, no calcium/vitamin D supplement in patients with increased osteoporotic risk, no influenza vaccination, no laxative in patients taking opioids.
dFor example, monitor glycaemia, kidney function, potential ADRs, potential DDIs, or observe the effectiveness of a treatment change.
eFor example, lifestyle advice towards the patient including diet and exercise, information about medication, information towards GP about untreated
symptoms.
fFor example, time interval between medication intake (eg, levothyroxine) and food intake.
gFor example, instruction of inhaler or eye drop technique.
hFor example, addition of missing contraindications or OTC‐medications to the patient's electronic pharmacy record.
iThe percentage within total number of DRPs.
jThe percentage within DRP subtype.
FOUBERT ET AL. 7with the GheOP3S‐tool, detection of “other DRPs,” and formulating
recommendations) 50 (30‐70) minutes, pharmacist‐GP meeting 15(10‐28) minutes, discussion with the patient 15 (10‐30) minutes, and
3‐month follow‐up 10 (5‐20) minutes.
TABLE 3 Acceptance and implementation rate (%) of pharmacists' recommendations (n = 426) per recommendation type (according to the
PharmDISC classification system)
Recommendation Type All DRPs n (%) Acceptance (%) Implementation (%)
D5 Therapy stopped 105 (24.6) 66 (62.9) 37 (35.2)
D1 Substitution 87 (20.4) 53 (60.9) 22 (25.3)
D2 Dose adjustment 60 (14.1) 39 (65.0) 17 (28.3)
D12 Therapy monitoring 57 (13.4) 45 (78.9) 31 (54.4)
D6 Therapy started 40 (9.4) 32 (80.0) 20 (50.0)
D11 Transmission of information 40 (9.4) 25 (62.5) 25 (62.5)
D4 Optimization of administration/route 17 (4.0) 14 (82.4) 11 (64.7)
D8 Application instruction (training) 8 (1.9) 5(62.5) 8 (100.0)a
D10 Clarification/addition of information to the patient's pharmacy record 6 (1.4) 3 (50.0) 6 (100.0)a
D7 In‐depth counselling of patient (eg, on adherence) 6 (1.4) 3 (50.0) 6 (100.0)a
Note. Acceptance and implementation rate are calculated per recommendation type.
aImplementation is higher than acceptance due to recommendations that were not accepted, but implemented; or recommendations of which the accep-
tance was not recorded that were nonetheless implemented.
Abbreviations: DRP, drug‐related problem; PharmDISC, Pharmacists' Documentation of Interventions in Seamless Care.
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The number of chronic medications had remained unchanged between
baseline and 3‐month follow‐up, while the number of “as needed”
medications had slightly decreased (P = .002) (Appendix S2). At 3‐
month follow‐up, the number of “GheOP3S‐related DRPs” (P < .001)
significantly decreased (Appendix S2). Furthermore, the DBI score
was slightly lower at follow‐up (versus baseline) (P = .033), but the
medication costs had remained unchanged (Appendix S2).4 | DISCUSSION
In this study, we investigated a community pharmacist‐led medication
review process (including a face‐to‐face meeting with both the patient
and the GP) in older patients with polypharmacy using the GheOP3S‐
tool. The GheOP3S‐tool served as a structured evidence–based aid to
detect DRPs with high clinical relevance for older patients and to ini-
tiate medication review in a community pharmacy setting without
the patient's clinical information.
The high number of detected DRPs (median (IQR) of 6 (4‐8) per
patient) highlights the relevance of performing medication reviews in
this population. Most prevalent detected DRPs comprised overuse
and misuse of potentially inappropriate medications, missing patient
documentation or information and underuse.
Our study showed a relatively high (67%) overall acceptance rate
of pharmacists' recommendations. This is in accordance with other
studies investigating pharmacist‐led medication reviews34,35 and dem-
onstrates that GPs were indeed (this was an inclusion criterion) willing
to collaborate during the face‐to‐face meetings. Less challenging rec-
ommendations (eg, optimization of administration, start medication,
and therapy monitoring) were most likely to be accepted. In most
cases of nonacceptance, the GP perceived that the medication neededto be continued or that the recommendation was currently of inferior
priority. Although we did not investigate the clinical relevance of these
recommendations, a possible explanation for not accepting certain
recommendations could be “inertia.”36 This means that the GP per-
ceives stopping medication as a lower value recommendation than
continuing medication (eg, because of fear for negative consequences
or minimization of the medication inappropriateness). The fact that
certain DRPs and their related recommendations were perceived to
be of inferior priority underlines the need for prioritizing actions (eg,
to make a top three of agreed actions) instead of engaging to imple-
ment all recommendations. Some of the “not recorded” acceptance
or implementation could be a result of this prioritization, but this
was not clear from the CRF. Nonetheless, periodic medication
reviews should regularly reassess the willingness to act upon these
recommendations.
Remarkably, about half (56%) of the accepted recommendations
were implemented. Other studies have reported similar implementa-
tion rates.37,38 The two main reasons for not implementing accepted
recommendations were patient refusal and postponement of the
intervention. It seemed that adjustments in the use of potentially inap-
propriate medications such as benzodiazepines/Z‐drugs, antidepres-
sants, proton pump inhibitors, and anticholinergics were not that
easy to implement for both the GP and the patient. A systematic
review performed by Reeve et al emphasizes the role of patients in
this process and described several patient reported barriers.39 Patients
can perceive the cessation of medication as inappropriate (eg, when
medication is perceived as currently necessary/beneficial or when
the patient accepts his medical condition and therefore the need for
medication). In addition, patients could fear the return of the condition
or withdrawal symptoms when medication is stopped.40 Conse-
quently, it is crucial that patients are well informed about the pro-
posed interventions. This information should be streamlined
between the pharmacist and GP, so both can convey the same
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tion between pharmacist and GP to reinforce trust and their profes-
sional relationship could lead to higher acceptance and
implementation rates.37 In addition, introducing extra follow‐up
moments could increase the actual implementation of interventions
that were postponed.
About half of the detected DRPs were related to GheOP3S‐criteria.
Most prevalent GheOP3S‐criteria comprised the overuse or misuse of
potentially inappropriate medications and underuse. Most frequently
involved medications were benzodiazepines, antidepressants,
calcium/vitamin D, PPIs, and anticholinergics, which is also regularly
reported in other studies.41,42 Pharmacists also detected a large num-
ber of “other DRPs” (51%), which consisted of a variety of DRP types.
Prevalent “other DRPs” encompassed DRPs such as “missing patient
documentation or information” (eg, untreated symptoms or medica-
tions not present in the electronic pharmacy record), “adverse effect,”
and “financial burden.” These types of DRPs cannot be detected by
merely screening a medication list with the help of an explicit screen-
ing tool. Patient involvement by including a patient interview in the
medication review process is a key factor to detect these additional
types of DRPs.43,44 This is supported by our finding that 26% of all
detected DRPs were only detected on the basis of the patient inter-
view. Notwithstanding the different types of “GheOP3S‐related DRPs”
and “other DRPs,” the acceptance and implementation rate of pharma-
cists' recommendations for both types of DRPs were similar.
An essential factor that needs to be tackled to implement medi-
cation reviews on a larger scale is the considerable time investment.
Pharmacists reported a median of 180 minutes to complete the
whole review, which has also been reported in literature on
pharmacist‐led medication reviews.45,46 The patient interview and
medication screening were the main contributing factors. We believe
that more education about communication (eg, techniques to guide
the conversation) and more training and experience in performing
medication reviews could counter this. Facilitated interdisciplinary
information exchange with access (before starting a medication
review) to already available patient information (eg, diagnoses, previ-
ous and most recent laboratory parameters, actual medication use
with start/stop dates of medications, contraindications, and reported
ADRs) could lead to more accurate information and could therefore
decrease time investment. Development of a software application of
the GheOP3S‐tool should facilitate medication screening in
the pharmacy. In addition, the substantial time investment advocates
targeting high‐risk patients (eg, prescribed 10 or more medications,47
using high‐risk medication,4,47 multimorbidity,48 cognitive impair-
ment,4 nonadherence,4 renal impairment,4 experience of ADRs,4
and high frailty score4) instead of all older patients with
polypharmacy.
At follow‐up, we observed a positive impact on the number of
“GheOP3S‐related DRPs” and the anticholinergic and sedative burden
(DBI scores), which could have clinical implications for the patient.
Our study has several strengths. First, this is the first study explor-
ing the use and potential impact of the GheOP3S‐tool during a multi-
disciplinary medication review in an ambulatory primary care setting.Second, this study combined the use of an explicit screening tool,
the GheOP3S‐tool, with a patient‐centred approach (eg, including
patient interviews) to detect additional DRPs.
Although the results of the present study are promising, there are
some limitations that should be taken into account. First, participating
pharmacists were presumably more motivated as most of them
volunteered to participate (participation bias). Pharmacists probably
selected GPs who were more likely to engage in a pharmacist‐GP col-
laboration and patients of whom they thought could benefit from a
medication review (selection bias). This could have led to higher
acceptance rates and could limit the generalizability. Second, the
observational design of this study could only detect a “potential”
impact of the intervention on different outcomes. In addition, we were
not able to assess medication appropriateness or clinical relevance of
pharmacists' recommendations due to incomplete data. Noteworthy,
the detection of DRPs in this study was primarily based on data from
the electronic pharmacy record (eg, dispensed medications, certain
contraindications, and allergies) and from the patient interview (eg,
the actual medication use and problems and experiences with medica-
tions). Pharmacists could contact the GP for additional information
during the pharmacotherapeutic analysis, but they had no access to
the GP's medical records. In addition, studies investigating medication
review processes often have different designs and settings, which
hinder a forthright comparison in acceptance and implementation of
pharmacists' recommendations.
Future larger sampled (longer‐term) studies should determine the
impact of this medication review process on patient‐centred out-
comes. A full cost‐effectiveness analysis should also be performed in
the future.5 | CONCLUSION
This study demonstrates that a multidisciplinary pharmacist‐led med-
ication review including a patient interview, screening with the
GheOP3S‐tool and face‐to‐face pharmacist‐GP meetings detects a
high number of DRPs. The acceptance rate of pharmacists' recom-
mendations was relatively high, although this did not translate into
a similar implementation rate. At follow‐up, the number of
“GheOP3S‐related DRPs” and the anticholinergic and sedative bur-
den of patients were reduced, which illustrates the potential positive
impact of pharmacists performing medication reviews in collabora-
tion with GPs. Future studies should focus on higher‐risk patients
to efficiently allocate time, ensure patient involvement (shared deci-
sion making), and collaboration between pharmacists and GPs to
establish trust and streamline information.ACKNOWLEDGEMENTS
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